Validation of the DCTclock drawing task as a cognitive screening tool for prodromal Alzheimers disease in the Framingham Heart Study

在弗雷明汉心脏研究中验证 DCTclock 绘图任务作为前驱阿尔茨海默病的认知筛查工具

• 批准号: 10214193
• 负责人: Louisa Thompson
• 金额: $ 23.15万
• 依托单位: BROWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10214193
• 关键词: Address; Administrator; Adult; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Alzheimer’s disease biomarker; Amyloid; Amyloid beta-Protein; Behavior; Biological Markers; Brain; Cerebrum; Clinic; Clinical Research; Clinical Trials; Cognition; Cognitive; Cohort Studies; Communities; Computer software; Data; Databases; Dementia; Detection; Development; Diagnosis; Disease; Disease susceptibility; Early Diagnosis; Elderly; FDA approved; Foundations; Framingham Heart Study; Funding; Future; Genetic Markers; Genetic Risk; Genotype; Goals; Health Professional; Hippocampus (Brain); Hospitals; Impaired cognition; Individual; Infarction; Intervention; Journals; Liquid substance; Machine Learning; Magnetic Resonance Imaging; Massachusetts; Measures; Medicare; Methods; Monitor; Neuropsychological Tests; Neuropsychology; Organizational Decision Making; Parietal; Participant; Patients; Peer Review; Performance; Persons; Population; Positron-Emission Tomography; Prevention Research; Primary Health Care; Publishing; Research; Risk; Sample Size; Sampling; Screening procedure; Secure; Statutes and Laws; Technology; Testing; Thick; Time; Validation; White Matter Hyperintensity; Work; abeta deposition; amnestic mild cognitive impairment; base; cerebrovascular; clinical care; cognitive change; cognitive testing; cost; cost effective; digital; genome wide association study; gray matter; health disparity; imaging biomarker; improved; indexing; medical specialties; mental state; mild cognitive impairment; multimodality; neuroimaging; neuroimaging marker; neuropathology; normal aging; patient screening; primary care setting; processing speed; prodromal Alzheimer' s disease; prognostic; prospective; recruit; screening; socioeconomics; validation studies; β-amyloid burden

Abstract. The diagnosis of probable Alzheimer’s disease (AD) has traditionally depended on fluid biomarkers and neuroimaging. However, these tests are often invasive, expensive, and generally available only in specialty clinics. Common neuropsychological tests used to screen for dementia (e.g., Mini-Mental State Examination) are not sensitive enough to detect early cognitive changes that can predict the emergence of prodromal AD. The DCTclockTM is an FDA approved digital neuropsychological test with the potential to be deployed in primary care and clinical trials research as a non-invasive and cost-effective screening tool for detecting the earliest stages of AD. The DCTclockTM can be easily administered by any healthcare professional and uses cutting-edge methods to capture nuanced neuropsychological behavior. Initial studies suggest that the DCTclockTM has high sensitivity to predict cortical amyloid (Aß) deposition and parietal hypometabolism on neuroimaging, suggesting that it could serve as a surrogate for more invasive or costly biomarker testing. This project will validate the DCTclockTM in a large sample of older adults from the Framingham Heart Study (FHS), using cross sectional and longitudinal approaches with the goals of determining: (1) the DCTclock’s ability to distinguishing mild cognitive impairment (MCI) from normal aging relative to existing cognitive screening measures, (2) its associations with genetic biomarkers of AD and neuroimaging measures of AD pathology, including MRI metrics and brain Aß levels on a PET scan. DCTclockTM drawing data has been collected in the FHS since 2011 from over 1,600 older adults without dementia, making it an ideal database for this validation study.

抽象的。传统上，可能的阿尔茨海默氏病（AD）诊断取决于流体生物标志物 和神经影像学。但是，这些测试通常是侵入性的，昂贵的，通常仅在专业中使用 诊所。用于筛查痴呆症的常见神经心理学测试（例如，小精神状态检查）是 敏感的不足以检测早期的认知变化，可以预测前驱AD的出现。 DCTClockTM是FDA批准的数字神经心理学测试，有可能部署在初级保健中 和临床试验研究是一种无创和具有成本效益的筛查工具，用于检测最早的阶段 广告。 DCTCLOCKTM可以轻松地由任何医疗保健专业人员管理，并使用尖端 捕获细微的神经心理学行为的方法。初步研究表明DCTClockTM具有很高的 对预测皮质淀粉样蛋白（Aß）沉积和顶质缺乏代谢的敏感性，表明 它可以作为更具侵入性或昂贵的生物标志物测试的代孕。该项目将验证 使用横截面 以及确定目标的纵向方法：（1）DCTClock区分中期的能力 认知障碍（MCI）从正常衰老相对于现有的认知筛查措施，（2） 与AD的遗传生物标志物和AD病理的神经成像指标的关联，包括MRI指标 和BrainAß水平进行PET扫描。自2011年以来，FHS已收集了DCTClockTM绘图数据 超过1,600名没有痴呆症的老年人，使其成为这项验证研究的理想数据库。